Monrol and MTTI ink Lu-177 supply deal

By staff writers

November 19, 2021 -- EczacıbaŞı-Monrol Nuclear Products has signed an agreement to supply Molecular Targeting Technologies (MTTI) with no-carrier-added lutetium-177 (Lu-177).

MTTI is focused on developing innovative therapies for rare cancers. A sustainable supply of the isotope from Monrol will help the company to move forward with the launch of its lead asset, Lu-177 EBTATE, as well as other EB (Evans blue) platform technologies, company representatives said.

Monrol, based in Istanbul, Turkey, is an international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking